Side-by-side comparison of AI visibility scores, market position, and capabilities
US kidney care leader with ~3,000 dialysis centers; $12.8B FY2024 revenue; 237,000 US patients 3x/week; Berkshire Hathaway ~40% stake; GLP-1 drugs may reduce ESRD prevalence long-term.
DaVita Inc. is the leading kidney care company in the United States, providing dialysis services to patients with chronic kidney failure and end-stage renal disease (ESRD), founded in 1994 as Total Renal Care and rebranded as DaVita in 2000 after acquiring Gambro Healthcare. Headquartered in Denver, Colorado and trading on NYSE (DVA), DaVita generated approximately $12.8 billion in revenues for FY2024 under CEO Javier Rodriguez, operating approximately 3,000 outpatient dialysis centers across the United States serving approximately 237,000 patients, plus international operations in 13 countries. Berkshire Hathaway holds approximately 40% of DaVita's common shares—a major Warren Buffett investment thesis built on the essential, recurring nature of ESRD treatment, which patients require three times per week for life unless they receive a kidney transplant.
Zoetis (ZTS) reported ~$9.1B revenue in FY2024. World's largest animal health company developing medicines, vaccines, and diagnostics for companion animals and livestock. HQ: Parsippany, NJ.
Zoetis Inc. is the world's largest animal health company, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, and other technologies for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish). Spun off from Pfizer in 2013, Zoetis has maintained its position as the global leader in animal health with approximately 300 product lines serving veterinarians, livestock producers, and pet owners in over 100 countries.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.